Re:Big Pharma spends billions more on executives and stockho...
by graemep on Saturday February 17, 2024 @06:08AM
(#39408405)
In very few cases are you talking about a system as inefficient as funding R & D.
It is not really an open market with competition: the government creates incentives, and only a faction of the increased cost to buyers goes into what the incentives are supposed to support.
It is not really an open market with competition: the government creates incentives, and only a faction of the increased cost to buyers goes into what the incentives are supposed to support.
Any useful information from price signals is lost too amid bad incentives: https://pietersz.co.uk/2007/01/pharmaceutical-incentives-dev...